Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Nov 15;5(2):127–150. doi: 10.1007/s41030-019-00104-6

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2019

Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any non-commercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

PMC Copyright notice

Fig. 3 — Systemic pharmacokinetics of phospholipid-based formulations following single dose administration of various ciprofloxacin formulations [27, 39, 55]. CFI (ciprofloxacin for inhalation) represents the liposomal component of the dual-release CDI (ciprofloxacin dispersion for inhalation) comprising a combination of liposomal and free drug. CIP (ciprofloxacin inhalation powder) is a dry powder formulation of ciprofloxacin. Note that the dose of liposomal ciprofloxacin administered in CFI is two times higher than that in CDI. The points presented above were determined experimentally [27, 39], while the curves represent fits to a compartmental pharmacokinetic model [55]. Reproduced with permission from Mary Ann Liebert, Inc. [55]